

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application. Please add new claims 11-13, as follows:

1. (Original) A prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors.
2. (Original) A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors comprises a) a 5-HT<sub>2B</sub> receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT<sub>2B</sub> receptor, and b) a 5-HT<sub>7</sub> receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT<sub>7</sub> receptor.
3. (Original) A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors comprises a dual antagonistic compound for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors having a selective binding affinity to both of the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors.
4. (Original) A combined prophylactic preparation for migraine which comprises a) a first pharmaceutical preparation comprising as an active ingredient a 5-HT<sub>2B</sub> receptor antagonistic compound having a selective binding affinity to the 5-HT<sub>2B</sub> receptor, and b) a second pharmaceutical preparation comprising as an active ingredient a 5-HT<sub>7</sub> receptor antagonistic compound having a selective binding affinity to the 5-HT<sub>7</sub> receptor, and wherein the first and second preparations are administered simultaneously or separately.

5. (Previously Presented) A prophylactic antimigraine agent as claimed in Claim 1, wherein the binding affinity for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors is respectively one hundredth or more to the  $\alpha_1$ , M<sub>1</sub>, D<sub>2</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub> and 5-HT<sub>6</sub> receptors.

6. (Original) Use of the selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors for the manufacture of a prophylactic antimigraine agent.

7. (Original) Use of "a 5-HT<sub>2B</sub> receptor antagonistic compound having a selective binding affinity to the 5-HT<sub>2B</sub> receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors.

8. (Original) Use of "a 5-HT<sub>7</sub> receptor antagonistic compound having a selective binding affinity to the 5-HT<sub>7</sub> receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors.

9. (Original) A method for prophylaxis of migraine which comprises administering a therapeutically effective amount of a selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors to a patient.

10. (Original) A method for prophylaxis of migraine which comprises administering a combination comprising a pharmaceutical preparation containing as an

active ingredient a 5-HT<sub>2B</sub> selective receptor antagonistic compound and a pharmaceutical preparation containing as an active ingredient a 5-HT<sub>7</sub> receptor selective antagonistic compound, simultaneously or separately to a patient.

11. (New) The method of claim 9, wherein the selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors comprises:

- a) a 5-HT<sub>2B</sub> receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT<sub>2B</sub> receptor, and
- b) a 5-HT<sub>7</sub> receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT<sub>7</sub> receptor.

12. (New) The method of claim 9, wherein the selective dual antagonist for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors comprises a dual antagonistic compound for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors having a selective binding affinity to both of the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors.

13. (New) The method of claim 9, wherein the binding affinity for the 5-HT<sub>2B</sub> and 5-HT<sub>7</sub> receptors is respectively one-hundredth or more to the  $\alpha_1$ , M<sub>1</sub>, D<sub>2</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub> and 5-HT<sub>6</sub> receptors.